Endovalve makes progress with percutaneous valve replacement:
This article was originally published in Clinica
Executive Summary
Endovalve has met some early milestones regarding the development of its percutaneous valve replacement system for treating mitral regurgitation. It has developed a to-scale functional model of the valve and anchor design, and has successfully demonstrated such feasibility criteria as foldability and deployment of the nitinol and stainless steel device, said the Princeton, New Jersey company. Bench testing on ex vivo sheep hearts has shown that when the valve device drops from the left atrium into the native mitral valve, it pushes away the native leaflets and is seated in place. The product's valve claws have also been shown to be able to "anchor" themselves onto the native annulus. Endovalve is now working on refining and optimising the valve's functionality, with a view to implanting the device in a live animal model.
You may also be interested in...
Source: 3 Former Obama US CMS Officials Being Considered To Lead Biden’s Medicare Agency
The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.
Hikma Opens Discussions To Acquire GSK OTC, Rx Businesses In Egypt, Tunisia
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
Pfizer's Xeljanz Post-Marketing Study Raises Safety Alarms
A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: